A second-generation recombinant BCG strain combines protection against murine tuberculosis with an enhanced safety profile in immunocompromised hosts

Valencia-Hernandez, Ana Maria;Zhao, Guangzu;Miranda-Hernandez, Socorro;Segura-Cerda, Cristian Alfredo;Pedroza-Roldan, Cesar;Seifert, Julia;Aceves-Sanchez, Michel de Jesus;Burciaga-Flores, Mirna;Gutierrez-Ortega, Abel;del Pozo-Ramos, Lidia Maria;Flores-Valdez, Mario Alberto;Kupz, Andreas

Ana Maria Valencia Hernandez

Abstract

Bacille Calmette-Guérin (BCG) remains the only licensed vaccine against tuberculosis (TB). While BCG protects against TB in children, its protection against pulmonary TB in adults is suboptimal, and the development of a better TB vaccine is a global health priority. Previously, we reported two recombinant BCG strains effective against murine TB with low virulence and lung pathology in immunocompromised mice and guinea pigs. We have recently combined these two recombinant BCG strains into one novel vaccine candidate (BCGΔBCG1419c::ESAT6-PE25SS) and evaluated its immunogenicity, efficacy and safety profile in mice. This new vaccine candidate is non-inferior to BCG in protection against TB, presents reduced pro-inflammatory immune responses and displays an enhanced safety profile.

Journal

Vaccine

Publication Name

N/A

Volume

ISBN/ISSN

1873-2518

Edition

N/A

Issue

N/A

Pages Count

Location

N/A

Publisher

Elsevier

Publisher Url

N/A

Publisher Location

N/A

Publish Date

N/A

Url

N/A

Date

N/A

EISSN

N/A

DOI

10.1016/j.vaccine.2024.126291